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The cytochromes P450 (CYP or P450) are a large superfamily of haem-
containing enzymes found in all domains of life. They catalyse a variety of
complex reactions, predominantly mixed-function oxidations, often displaying
highly regio- and/or stereospecific chemistry. In streptomycetes, they are
predominantly associated with secondary metabolite biosynthetic pathways or
with xenobiotic catabolism. Homologues of one family, CYP105, have been
found in all Streptomyces species thus far sequenced. This review looks at the
diverse biological functions of CYP105s and the biosynthetic/catabolic
pathways they are associated with. Examples are presented showing a range of
biotransformative abilities and different contexts. As biocatalysts capable of
some remarkable chemistry, CYP105s have great biotechnological potential and
merit detailed study. Recent developments in biotechnological applications
which utilize CYP105s are described, alongside a brief overview of the benefits
and drawbacks of using P450s in commercial applications. The role of
CYP105s in vivo is in many cases undefined and provides a rich source for
further investigation into the functions these enzymes fulfil and the metabolic
pathways they participate in, in the natural environment.
Introduction
The cytochromes P450 are a superfamily of haemopro-
teins, first identified in mammalian liver microsomes
(Omura and Sato 1962). They were found to be involved
in the production of steroid hormones such as progester-
one and play important roles in drug and xenobiotic
metabolism (Omura 1993). P450s have since been found
in animals, plants, fungi and bacteria, displaying a diverse
range of functions from biosynthesis of sterols to the
breakdown of aromatic petrochemicals (Ichinose 2012).
They catalyse a variety of NADPH/NADH- and
O2-dependent reactions including hydroxylation; alcohol
and carbonyl oxidation; epoxidation; dealkylation; hetero-
atom oxidation; desaturation; ring cleavage, expansion,
coupling and formation; dehydration; and even reduction
(Guengerich and Munro 2013). According to the widely
accepted P450 nomenclature system (Nelson 2009), a
pairwise amino acid sequence identity of 40% is required
to assign proteins within the same P450 family (e.g.
CYP105), and 55% identity is required for assignment
within the same subfamily (e.g. CYP105A).
In bacteria, the occurrence of P450s is highly variable.
While the Escherichia coli genome has no identified
P450s, many other species contain multiple P450 homo-
logues. Some of the first examples of bacterial P450s to
be identified include P450cam (CYP101A1) in Pseudomo-
nas putida (Sligar et al. 1974) and P450BM3 (CYP102A1)
in Bacillus megaterium (Fulco 1991). Every actinomycete
species that has had its genome sequenced has revealed
an abundance of P450s. For example, Streptomyces coeli-
color has 18 P450s (Lamb et al. 2002), Mycobacterium
tuberculosis has 20 (McLean et al. 2006), and Streptomyces
avermitilis has 33 putative P450s (Ikeda et al. 2003; Lamb
et al. 2003). CYP105s are predominantly found in bacte-
ria belonging to the phylum Actinobacteria and the order
Actinomycetales, with the exception of CYP105T1 which
is found in Burkholderia fungorum, in the phylum
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Proteobacteria (based on those proteins named in the
P450 nomenclature system at http://drnelson.uthsc.edu/
bacterial.P450s.2011.htm). A review of current literature
suggests that CYP105 may be uniquely conserved as
the only P450 family with representatives in every
streptomycete species thus far investigated (also in Tak-
amatsu et al. 2011). The CYP105 family has at least 17
subfamilies represented in streptomycetes (Fig. 1 and
Table 1), with their roles falling broadly into two catego-
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Figure 1 Phylogenetic tree of CYP105 homologues in Streptomyces. Amino acid sequences for CYP105s in Streptomyces spp. were aligned (Sie-
vers et al. 2013) and a phylogenetic tree generated. The tree was obtained in Mega6 using the neighbour-joining method (Tamura et al. 2013).
The values shown are confidence percentages based on a bootstrap value of 500 repetitions. The scale bar (top left) indicates a genetic change
of 02. Only CYP105s assigned to a subfamily by Nelson (http://drnelson.uthsc.edu/CytochromeP450.html) are included, so the list should not be
considered exhaustive. Also included were examples of CYP105 enzymes from other actinomycete genera, MoxA from Nonomuraea recticatena
and a CYP105 from Kutzneria. The final proteins included as comparators were CYP170A1, a well-characterized P450 from Streptomyces coeli-
color, and CYP2R1, a human P450 with low level amino acid homology to CYP105 enzymes.
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and biosynthesis of specialized bioactive molecules. This
functional diversity suggests there is considerable varia-
tion in structure within the family.
CYP105s are associated with a wide variety of pathways
and processes, from steroid biotransformation to produc-
tion of macrolide metabolites (see below). Individual
P450s, including CYP105s, may also be capable of cataly-
sing diverse reactions, with one enzyme capable of cataly-
sing a range of reactions with a variety of structurally
different compounds (e.g. Kittendorf and Sherman
2009). For example, CYP105A1 catalyses two sequential
hydroxylations of vitamin D3 with differing specificity
(Sugimoto et al. 2008), and CYP105D1 has been shown
to be capable of both oxidation (Taylor et al. 1999) and
dealkylation reactions (Ueno et al. 2005). The low level
of substrate stringency exhibited by some of these
enzymes makes them potentially interesting for engineer-
ing novel compounds from related substrates. Many
other CYP105s, on the other hand, demonstrate high
substrate and site specificity. This is often true of P450s
which act as part of a biosynthetic process (Podust and
Sherman 2012). For example, CYP105D6 and CYP105P1
in the filipin biosynthetic pathway perform highly regio-
and stereospecific hydroxylations (Xu et al. 2010). This
review aims to highlight the diversity of CYP105
structures and catalytic functions; CYP105s involved in
Table 1 The complete CYP105 proteins from Streptomyces listed on the Cytochrome P450 homepage (http://drnelson.uthsc.edu/Cyto-
chromeP450.html), with those mentioned in the text that have yet to be assigned within official P450 nomenclature included
CYP105 Uniprot ID Species of Streptomyces Function (if known)
A1 P18326 griseolus Wide range (see text)*,†
A3 Q59831 carbophilus Pravastatin synthesis†
B1 P18327 griseolus Sulfonylurea oxidation*
B2 Q595R4 tubercidicus Avermectin oxidation†
C1 P23296 sp.
C- A6YRR3 virginiae Steroid oxidation*
D1 P26911 griseus Xenobiotic degradation*
D4 O85697 lividans
D5 Q9EWS4 coelicolor Fatty acids‡
D6 Q79ZT5 avermitilis Filipin C10‡
D7 Q825I8 avermitilis Pentalenic acid, xenobiotics*,‡
D8 Q595S4 tubercidicus strain I-1529 Avermectin oxidation†
D9 Q8KSY0 sp. JP95 Griseorhodin‡
F1 Q9X5P8 lavendulae Unknown polyketide
F2 Q70AS0 peucetius Oleandomycin oxidation‡
H1 Q9L4W8 noursei ATCC 11455 Nystatin‡
H3 Q9EW94 natalensis Pimaricin‡
H4 Q93NX1 nodosus Amphotericin‡
H5 Q9EWC4 griseus Candidicin‡
K1 Q9X9P7 tendae strain Tue901 Nikkomycin‡
K2 Q8RNW8 ansochromogenes Nikkomycin‡
L1 Q9ZHQ1 fradiae Tylosin‡
M1 Q9KJ93 clavuligerus Clavulanic acid‡
N1 Q9EWP1 coelicolor Coelibactin‡
N- D6ESR2 lividans Putatively coelibactin‡
N- D9XRK0 griseoflavus Putatively coelibactin‡
N- G2NQM5 SirexAA-E Putatively coelibactin‡
P1 Q79ZT4 avermitilis Filipin C26‡




U1 Q84G11 hygroscopicus strain NRRL3602 Geldanamycin‡
V1 Q6V1N2 sp. HK803 Phoslactomycin‡
Z1 C9ZGE5 scabies strain 8722
AA1 Q595R1 tubercidicus strain R922 Avermectin oxidation†
AA2 Q595S0 tubercidicus strain I-1529 Avermectin oxidation†
In the final column, *indicates a xenobiotic breakdown function, †a biotechnological use and ‡indicates the biosynthetic pathway the protein is
associated with.
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xenobiotic degradation and their potential use in bio-
remediation; those involved in biosynthesis of useful bio-
active molecules; and those which have proved amenable
to biotechnological applications. While CYP105s have
been known for many years, the last decade has seen a
rapid rise in both structural and functional studies, with
the result that several of these enzymes are now being
utilized (and modified for use) in novel biotechnological
applications.
CYP105s involved in xenobiotic catabolism
The P450 superfamily is well known for its roles in
detoxification of xenobiotic compounds (Omura 1993),
and it is therefore unsurprising that early work on
CYP105s focused on this ability. Although the CYP105
family has several examples of involvement in degrada-
tion of xenobiotic compounds, the ecological context of
this function is not always clear, as an enzyme capable of
metabolizing numerous xenobiotics is often researched
more in the context of biotechnology and less for the
specialized metabolism required in the environmental
niche the cell occupies. For example, CYP105D1 from
Streptomyces griseus has been shown to be capable of oxi-
dizing a diverse range of xenobiotics (Fig. 2) including
camphor (Sariaslani et al. 1990), benzo[a]pyrene, erythro-
mycin and warfarin (Taylor et al. 1999) and can catalyse
the oxidative dealkylation of 7-ethoxycoumarin (Ueno
et al. 2005). These studies, however, were conducted
using heterologously expressed protein, so the role, sub-
strate and catalytic function of the P450 in the native
streptomycete cell remain unknown. More interesting,
perhaps, is a study of the correlation between the pres-
ence of toxic herbicides and the action of CYP105A1 and
CYP105B1 in Streptomyces griseolus. Not only are these
enzymes capable of metabolizing sulfonylurea herbicides
(Fig. 2) to less toxic compounds (O’Keefe et al. 1988),
but production of P450s in the cell was induced by the
addition of the herbicide to the growth media (Romesser
and O’Keefe 1986). This suggests that the cell has the
ability to recognize and respond to the toxic compound
(or closely related compounds) in the environment and
that the observed in vitro xenobiotic biotransformation
may indeed occur in this species in nature.
More recent developments include an excellent exam-
ple of using knowledge of the species’ ecological niche to
inform further investigation. Streptomyces virginiae IBL14
was originally isolated from waste sludge from steroid
manufacture (Wang et al. 2007) and was found to
degrade a range of steroidal compounds including pro-
gesterone, cholesterol and hydrocortisone (Wang et al.
2009a) (Fig. 2). Streptomyces virginiae IBL14 contains five
predicted CYP105 homologues, of 33 P450s in total, and
several were linked to the xenobiotic degradative abilities
of the organism (Li et al. 2013). One was found to be
clustered with a cholesterol oxidase, suggesting a role in
oxidative transformation of cholesterol and possibly its
analogues, although this was not followed up experimen-
tally (Li et al. 2013). A CYP105C was isolated and its
degradative abilities confirmed in vitro. The CYP105C
was shown to catalyse conversion of diosgenin (a
platform compound used in the synthesis of a variety of
steroidal products) to isonuatigenone (a rare natural
steroidal sapogenin) via hydroxylation of the tertiary C25
(Wang et al. 2007, 2009b) (Fig. 2). Natural and synthetic
steroids are regarded as significant water pollutants due
to their ability to cause endocrine disruption, reproduc-
tive toxicity and damaging effects on mammalian cell
development (see Sun et al. 2013 for review). In the light
of this, S. virginiae IBL14 or processes utilizing the puri-
fied P450s may be useful for bioremediation of steroidal
compounds in wastewater. While xenobiotic metabolism
has been investigated as a property of CYP105 enzymes










































































Figure 2 Selected xenobiotic substrates of CYP105s. (a) Sulfonylurea
herbicide substrates of CYP105A1 from Streptomyces griseolus, (b)
steroid substrates of CYP105C from Streptomyces virginiae IBL14, (c)
reaction scheme for conversion of diosgenone to isonuatigenone by
CYP105C from S. virginiae IBL14 and (d) substrates of CYP105D1
from S. griseus discussed in the text. Except in the case of diosge-
none, where the modification is indicated, and 7-ethoxycoumarin,
which is dealkylated, the site of modification by the CYP105 has not
been identified.
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CYP105s in the biosynthetic pathways of
specialized metabolites
A driving factor in much of the research on streptomycetes
has been the abundance of secondary metabolites produced
by this genus. Over the last 10 years, there has been
increasing appreciation of the intricate tailoring role of
P450s in many biosynthetic pathways, as they are often
associated with the final steps of specialized metabolite
production, refining the final product by complex regio-
and stereospecific oxidative tailoring (Zhao and Waterman
2007). There are now several examples of CYP105s known
to play important roles in biosynthesis of bioactive mole-
cules (Fig. 3), and new pathways are still being revealed,
suggesting further CYP105 involvement may be uncovered.
Characterized streptomycete CYP105s are predomi-
nantly involved in polyketide biosynthesis. Several mem-
bers of the CYP105H subfamily catalyse oxidation of a
methyl group to a carboxylic acid in the biosynthesis of a
range of polyene antifungals (Fig. 3) (Aparicio et al.
2000; Brautaset et al. 2000; Gil and Campelo 2002;
Carmody et al. 2005). This three-step oxidation process
has a strong precedent in the CYP51-catalysed oxidative
demethylation of sterols (Akhtar et al. 1978; Lepesheva
and Waterman 2007). Other members of the CYP105
family catalyse simpler hydroxylation reactions in strepto-
mycete polyketide biosynthesis (Fig. 3). Biosynthesis of
the macrolide tylosin in Streptomyces fradiae involves
hydroxylation of the C23 methyl group by CYP105L1
and subsequent glycosylation of the hydroxyl (Fouces
et al. 1999). A further two members of the CYP105 fam-
ily form part of the biosynthetic pathway of the polyene
antifungal filipin in Streptomyces avermitilis (Xu et al.
2009). CYP105D6 and CYP105P1 in S. avermitilis catalyse
regiospecific hydroxylations at C10 and C26 of filipin,
































































































































































































Figure 3 Secondary metabolites whose biosynthesis requires the action of a CYP105. The structural feature introduced by the CYP105 is
arrowed, and the CYP105 involved is indicated. The site of modification of coelibactin is not known.
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Other known activities of CYP105s in polyketide bio-
synthesis (Fig. 3) include an epoxidation reaction in gri-
seorhodin biosynthesis, catalysed by CYP105D9 of
Streptomyces sp. JP95 (Yunt et al. 2009), and an apparent
hydroxylation–dehydration reaction catalysed by
CYP105U1 during biosynthesis of geldanamycin by Strep-
tomyces hygroscopicus (Li et al. 2012). In Streptomyces sp.
HK803, CYP105V1 catalyses a hydroxylation reaction in
the biosynthesis of phoslactomycin (Palaniappan et al.
2003). Other CYP105s are known to cluster with polyke-
tide biosynthesis genes, but their products are unknown.
For example, CYP105F1 of Streptomyces lavendulae is
known to be part of a polyketide synthase (PKS) cluster
adjacent to the cluster responsible for the biosynthesis of
the antibiotic mitomycin (Mao et al. 1999), and
CYP105R1 is part of the pks4 cluster in S. avermitilis
(Lamb et al. 2003).
CYP105s are also involved in the biosynthesis of other
classes of secondary metabolite (Fig. 3). Members of the
CYP105K subfamily catalyse an aromatic hydroxylation
reaction in the biosynthesis of the peptidyl nucleoside anti-
biotic nikkomycin, and CYP105M1 catalyses an oxidative
deamination in the biosynthesis of the clinically important
b-lactamase inhibitor clavulanic acid by Streptomyces cla-
vuligerus. CYP105D5 of S. coelicolor catalyses oxidation of
various fatty acids in vitro, and the in vitro products were
shown to also be produced in vivo, suggesting that this is
the true physiological role of the enzyme (Chun et al.
2007). Another member of the CYP105D subfamily,
CYP105D7 of S. avermitilis, is involved in the production
of pentalenic acid (Takamatsu et al. 2011). This is a known
cometabolite of pentalenolactone biosynthesis in other
organisms and is formed by CYP105D7-catalysed hydrox-
ylation at C1 of 1-deoxypentalenic acid, although the
encoding gene is not part of the pentalenolactone biosyn-
thesis cluster (Takamatsu et al. 2011). In addition to its
biosynthetic role, CYP105D7 was also able to catalyse oxi-
dation of a range of unrelated compounds, although it was
unable to oxidize pentalenolactone-related molecules other
than 1-deoxypentalenic acid (Takamatsu et al. 2011). Pen-
talenolactones are sesquiterpenoid antibiotics produced by
numerous streptomycetes. Sesquiterpenoids may have an
important and as yet undefined role in streptomycete biol-
ogy as several terpenoid biosynthetic pathways have been
shown to be highly conserved across many diverse species
(e.g. geosmin, Gerber and Lechevalier 1965; albaflavenone,
Moody et al. 2012). Terpenoids are often signalling mole-
cules in nature with roles as attractants, repellents and for
communicating information to a dispersed community
(see Gershenzon and Dudareva 2007, for review). Playing a
part in the biosynthesis of these potential signalling mole-
cules would define a new and exciting role for P450
enzymes in streptomycete biology.
CYP105N1 in S. coelicolor is an interesting example of
an enzyme involved in a cryptic biosynthetic pathway. The
coelibactin biosynthetic gene cluster of which it is a part
was identified by genome sequencing (Bentley et al. 2002).
This nonribosomal peptide synthetase (NRPS) cluster is
thought to produce a zinc-chelating siderophore, and gene
expression of the pathway has indeed been shown to be
responsive to zinc (Kallifidas et al. 2010), but the pathway
remains cryptic as the end product has yet to be detected
(Zhao et al. 2012). Bioinformatic analysis shows that this
subfamily is well conserved, with three other species of
streptomycetes possessing a homologue with over 90%
identity to CYP105N1: Streptomyces sp. Sirex AA-E, Strep-
tomyces griseoflavus and two strains of Streptomyces lividans
(TK24, which is included here, and 1326) (Fig. 1 and
Table 1). The extremely high sequence homology within
the CYP105N subfamily suggests that they may have a
common substrate and function. Studying conservation of
P450 genes and proteins across the Streptomyces genus,
and examination of the genomic context in which P450s
are located, can begin to reveal the importance of their role
in streptomycete biology. The biochemistry of CYP105N
proteins and their function within the coelibactin pathway
are certainly intriguing avenues for further exploration.
Concurrent structural resolution and biocatalytic
characterization give the greatest insights
X-ray crystallographic determination of P450 structures
has proved to be essential for elucidating the mechanisms
of their biochemical function. The first bacterial P450 to
have its structure resolved was P450cam (CYP101A1) in
the 1980s (Poulos et al. 1987), and until the last decade,
there was a distinct paucity of bacterial P450s in the Pro-
tein Databank. Despite the conserved nature of CYP105s
across the Streptomyces genus, and interest in the
biochemistry of this family, the first crystal structure
of a CYP105, MoxA from the actinomycete species
Nonomuraea recticatena, was not published until 2007
(Yasutake et al.). Several actinomycete CYP105s have
since been crystallized and undergone structural resolu-
tion by X-ray crystallography. All CYP105s share the
common P450 structure, although in common with the
superfamily as a whole, only a small number of residues
are conserved throughout the CYP105 family (Fig. 4).
These are mostly in haem-binding regions and common
P450 motifs, such as the ExxR motif on Helix K and the
FxxGx(R/H)xCxxG motif (H in CYP105) on the haem-
binding loop before Helix L.
MoxA was found to be similar in function to mamma-
lian liver P450 enzymes in having broad substrate speci-
ficity and being able to metabolize a wide variety of
pharmaceutical compounds. Acceptable substrates for
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MoxA range from testosterone and oleanolic acid to vari-
ous luciferin derivatives of human liver P450 substrates
(Yasutake et al. 2007). Its reported catalytic abilities
include demethylation of luciferin 60-methyl ether and
debenzylation (the first CYP105 reported to have this
function) of luciferin 60-benzyl ether (Yasutake et al.
2007). While the activity of MoxA has been biochemically
characterized in vitro, its natural substrate and actual bio-
logical function remain unknown. It has been suggested
that binding pockets in the CYP105 family are able to
accommodate a wide diversity of structurally distinct sub-
strates (Kabumoto et al. 2009), yet the size and shape of
the binding pocket has been shown to be poorly corre-
lated to function and is not considered predictive of sub-
strate size (Yasutake et al. 2007). Thus, the broad
substrate specificity demonstrated for MoxA in vitro,
combined with the size and shape of the ligand-free bind-
ing pocket, may not supply many clues to the natural
substrate. Interestingly, the crystal structures of CYP105s
with broad substrate specificity do not demonstrate any
obvious active site differences to those of CYP105 mem-
bers with highly defined substrate specificity (Podust and
Sherman 2012). The great variation seen in CYP105 sub-
strates and products also makes prediction of putative
substrates or reactions for individual CYP105s problem-
atic. This is in contrast to some other streptomycete
P450s, such as CYP170. CYP170A1 from S. coelicolor, the
first in the family to be biochemically characterized, is
known to catalyse the allylic transformation of the sesqui-
terpene epi-isozizaene to an epimeric mixture of albafl-
avenols and finally to albaflavenone (Zhao et al. 2008).
The same catalytic ability was predicted in a variety of
streptomycete species encoding proteins from different
subfamilies of CYP170 (based on amino acid sequence
analysis), and they were experimentally demonstrated to
use the same substrate and give rise to the same product
(Moody et al. 2012).
Perhaps the best structurally characterized streptomy-
cete CYP105s are CYP105D6 and CYP105P1, both from
the filipin biosynthetic pathway in S. avermitilis. Both
proteins have been crystallized and had their structures
resolved by X-ray crystallography (Xu et al. 2009, 2010),
but importantly, CYP105P1 was also crystallized with the
substrate bound (Xu et al. 2010) (Fig. 5). In common
with many P450s, the FG helices in CYP105P1 are
mobile, changing from an open conformation to a closed
form on ligand binding. Additionally, the BC loop, which
contains 33 amino acid residues, does not have the helical
structure seen in most P450s and is thought to be highly
flexible (Xu et al. 2009). Both regions may provide access
for the filipin I molecule to the haem-binding site. The
crystal structures also suggested that the differing regio-
specificity of the two enzymes was due to the presence of
a subpocket lined with three glycine residues in
CYP105P1, which was occupied by the alkyl side chain of
filipin I, allowing accommodation of the bulky substrate
in a specific orientation. This pocket is absent in the
CYP105D6 crystal structure, with serine 290 and isoleu-
cine 293 preventing the alkyl chain, and therefore filipin I
itself, from binding in the same orientation as in
CYP105P1 (Xu et al. 2010). This demonstrates the
importance of both substrate-bound and substrate-free
































Figure 4 The crystal structure and sequence of CYP105N1 from
Streptomyces coelicolor, showing important features. (a) Cartoon rep-
resentation of CYP105N1 (PDB 3TYW, Zhao et al. 2012). Important
structural features are labelled, and bound haem is shown as sticks.
(b) Sequence of CYP105N1, showing secondary structural elements
based on PSB 3TYW. Residues that are completely (*), strongly (:) and
weakly (.) conserved (according to a ClustalW alignment) among the
CYP105 family are indicated. The colour scheme used for the second-
ary structure elements in panel a is shown in panel b.
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CYP105 catalysis and suggesting reasons for the observed
stereochemistry of the product. The large difference in
active site volume between the substrate-free and sub-
strate bound structures of CYP105P1 also cautions
against drawing too many conclusions from structures of
a free P450 (Xu et al. 2009, 2010). The work conducted
on CYP105D6 and CYP105P1 has allowed further appre-
ciation of the flexibility of the binding pocket and which
domains are likely to change conformation to accommo-
date various substrates.
CYP105A1 from S. griseolus is another interesting
example. Among its other functions, this enzyme is able
to catalyse the biotransformation of vitamin D3 (VD3) to
1a,25-dihydroxyvitamin D3 (1a,25-(OH)2D3) in two
sequential hydroxylation reactions (Sawada et al. 2004).
In mammals, VD3 is transformed from a prohormone to
its active state by two separate reactions, undergoing C25
hydroxylation in the liver and 1a-hydroxylation in the
kidney (Takeyama et al. 1997; Cheng et al. 2004). Analy-
sis of the resolved crystal structure of CYP105A1 (Fig. 6)
with and without 1a,25-(OH)2D3 in the binding pocket
revealed a common binding mode with human CYP2R1
for C25 hydroxylation (Sugimoto et al. 2008). Site-direc-
ted mutagenesis of the hydrophobic residues thought to
interact with 1a,25-(OH)2D3 (V88A, L180A and V181A)
all resulted in dramatic reduction in activity for both
conversion of VD3 to 25-(OH)D3 and of 25-(OH)D3 to
1a,25-(OH)2D3 (Sugimoto et al. 2008), while R73A and
R84A mutations greatly increased production of both
derivatives. This suggests that the same residues are
involved in controlling the specificity of both hydroxyl-
ation reactions in CYP105A1. Interaction between argi-
nine 193 and the hydroxyl group on the substrate was
also found to be important for both hydroxylation reac-
tions, as substitutions with alanine, glutamine or lysine
all decreased activity. Sugimoto et al. (2008) suggest that
the substrate enters the binding site for the first hydrox-
ylation event at C1, then exits and re-enters the binding
pocket in a different position to allow access to C25.
Clearly, given the low amino acid homology between
CYP105A1 and CYP2R1 (Fig. 1), prediction of the simi-
larity in biochemistry could not have been expected
based on primary sequence. This again highlights the
need for both structural and biochemical characteriza-
tion.
These examples demonstrate the need for structural
analysis both with the substrate in situ and with an unoc-
cupied binding pocket for clear understanding of the nat-
ure of the reactions catalysed by these enzymes. This is
particularly apparent for CYP105N1 from S. coelicolor,
involved in the cryptic coelibactin biosynthesis pathway,
whose crystal structure (Fig. 4) has been determined
(Zhao et al. 2012) but whose biochemistry remains
unknown. The predicted structure of coelibactin (Bentley
et al. 2002) was thought structurally unlikely to bind to
zinc, and it was proposed that CYP105N1 may modify
the post-NRPS molecule to enable zinc chelation (Zhao
et al. 2012). However, definitive answers are elusive
without experimental evidence because of the high diver-
sity of catalytic reactions conducted by CYP105 enzymes
and the poor correlation between the observed size
and shape of the binding pocket and the substrate it
binds to.
Homology modelling has also been used to investigate







Figure 5 Crystal structures of CYP105D6 and CYP105P1 from Strep-
tomyces avermitilis. (a) Overlaid cartoon representations of CYP105D6
(( ) D6, PDB 3ABB; Xu et al. 2010), CYP105P1 (( ) P1, PDB 3E5J; Xu
et al. 2009) and CYP105P1 with bound filipin I (( ) P1 + filipin, PDB
3ABA; Xu et al. 2010). Haem and filipin I (from PDB 3ABA) shown as
sticks. (b) Active site regions of CYP105D6 and CYP105P1, with resi-
dues responsible for the differing substrate specificity of the two
enzymes (see text), bound haem and filipin I shown as sticks.
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CYP105P2 from Streptomyces peucetius has been produced
and docked with a flavone substrate (Kanth et al. 2010).
It was subsequently shown that CYP105P2 is capable of
oxidizing flavones in vitro, in almost the same position as
predicted by the model (Niraula et al. 2012). Similarly,
CYP105F2 from S. peucetius has been shown to catalyse
specific C4 hydroxylation of the macrolide oleandomycin,
and a homology model has been produced, although
docking with oleandomycin was not attempted (Shrestha
et al. 2008). It was concluded that CYP105F2 is likely to
have relaxed substrate specificity, based on comparison of
the homology model to the crystal structures of other
P450s (Shrestha et al. 2008), although it has been shown
elsewhere that simple comparison of binding pockets in
the absence of bound substrates is uninformative (Podust
and Sherman 2012). Nevertheless, these studies show that
homology modelling and biochemical characterization
can be combined to provide insight into CYP105 func-
tion. Despite CYP105P2 being a very close homologue of
the structurally characterized CYP105P1 (Fig. 1), and
CYP105F2 being a close homologue of CYP105F1 from
S. lavendulae, which is part of the biosynthesis cluster of
an unknown polyketide (Mao et al. 1999), the native
function of both enzymes remains unknown. Establishing
their roles would be interesting as S. peucetius is not
known to make macrolide secondary metabolites.
In common with other P450s, the increasing number
of crystallized CYP105 proteins is a valuable resource,
both for understanding the chemistry and function of
individual P450s and identification of conserved traits—
both physical and catalytic. While much has been learned
in the past few decades from heterologous expression
studies about the catalytic abilities of all P450s and spe-
cifically CYP105s, a deeper understanding of substrate
binding mechanisms on the molecular level, be it through
experimental determination of structures or through
homology modelling and in silico docking, will certainly
enhance intelligent design or manipulation of CYP105
systems for development and use in industrial applica-
tions. Progress in both pharmaceutical development, for
example through the tailoring of molecules to reduce
drug toxicity or side effects, and applications to bioreme-
diation are more likely when the exact mechanisms of
biocatalysis are fully elucidated.
CYP105 proteins in biotechnology: utilization and
manipulation
P450s have been utilized in biotechnological applications
and in the production and modification of pharmaceuti-
cal compounds (e.g. Watanabe et al. 1995; Machida et al.
2009) and have proven to be amenable to manipulation
in heterologous expression systems, protein purification
and to rational mutagenic strategies to enhance desirable
biocatalytic properties (Grogan 2011). Modifications such
as alterations to the N-terminal region and adapting cod-
ing sequences to consider the codon bias of the produc-
ing cell have been tried, as have attempts at reducing











Figure 6 Crystal structure of CYP105A1 from Streptomyces griseo-
lus. (a) Cartoon representation of CYP105A1-R84A (PDB 2ZBZ,
Sugimoto et al. 2008) with bound haem and 1a,25-dihydroxyvitamin
D3 ((OH)2D3) shown as sticks. (b) Active site region of CYP105A1-
R84A, with important residues (see text), bound haem and (OH)2D3
shown as sticks. The same colour scheme is used for the secondary
structure elements as in Fig. 4.
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Codon bias is particularly pertinent with streptomycete
P450s as the Streptomyces genus has an unusually high
GC content (68–72%), which is not shared with a com-
mon expression host, E. coli. Despite the disparity in GC
content and consequent coding preference, the lack of
any endogenous P450s in E. coli makes this an ideal
expression host as high levels of purity can be achieved
for heterologously expressed P450s without contamina-
tion from native P450s. Bacterial P450s are, however, rel-
atively unstable with low catalytic activity and are
dependent on the presence of electron donor partners
(e.g. ferredoxin and ferredoxin reductase) which makes
them less suitable for bulk production and more useful
in high specification production such as the pharmaceuti-
cal industry (Sakaki 2012). In their favour, the bacterial
P450s thus far identified are cytosolic, as opposed to
many eukaryotic P450s which are membrane bound. This
is a clear advantage in terms of downstream biotechno-
logical applications as bacterial P450s are soluble, whereas
eukaryotic P450s require detergent treatment to solubilize
them prior to further use (Munro et al. 2013). Perhaps as
a consequence of this, bacterial P450s have been easier to
characterize than fungal or plant P450s both in terms of
function and structure (Podust and Sherman 2012), lead-
ing to more opportunities for their development as bio-
technological tools.
One of the most successful industrial applications of
CYP105 biocatalysis is in the production of the anti-
hyperlipidaemia drug, pravastatin. Compactin (mevasta-
tin), a metabolite of the fungus Penicillium citrinum,
undergoes biotransformation by CYP105A3 (also called
P450sca-2) in Streptomyces carbophilus to pravastatin via
a stereoselective 6b-hydroxylation (Watanabe et al. 1995)
(Fig. 7). The purified CYP105A3 has, more recently, been
subject to site-directed mutagenesis. A mutant with six
amino acid substitutions (G52S/F89I/P159A/D269E/
T323A/E370V) gave improved biotransformative activity
in whole cell extracts compared with the wild type
when heterologously expressed in E. coli, and this was
attributed to improvements in expression of active pro-
tein (Ba et al. 2013a). Further mutagenic studies targeted
the redoxin interaction interface (T119 and N363), the
substrate access channel (V194) and one residue within
the binding pocket (T85), with a view to improving the
enzyme kinetics. The resulting improved activity, particu-
larly related to the altered redoxin interface residues, was
attributed to enhanced electron transfer in the P450
redox system (Ba et al. 2013b). Similarly, CYP105A1 is
used industrially to catalyse the biotransformation of
VD3 to 1a,25-dihydroxyvitamin D3 (Sugimoto et al.
2008; see above), an important pharmaceutical product
for the treatment of osteoporosis and chronic renal fail-
ure among others. Site-directed mutagenesis was again
used to enhance the activity of this P450. Mutation of
the two arginine residues identified in structural studies
(Sugimoto et al. 2008; see above), to form the double
mutant R73V/R84A, gave large increases in the activity of
both hydroxylation events (400-fold for 25-hydroxylation
and 100-fold for 1a-hydroxylation) (Hayashi et al. 2008).
This progress may herald a new era in P450 utilization,
with enzymes used in well-established processes being
intelligently manipulated to increase their usefulness.
One filipin-producing species, Streptomyces miharaen-
sis, has been proposed as a biocontrol agent against a
range of commercially important fungal plant pathogens.
The filipin complex is a mixture of polyene macrolides
hydroxylated in slightly different positions, requiring the
action of a CYP105D and a CYP105P. This mixture is
produced by a variety of streptomycete species and dis-
plays potent antifungal activity (Ammann and Gottlieb
1955; Whitfield et al. 1955). Kim et al. (2012) reported
S. miharaensis-mediated inhibition of Alternaria mali,
Aspergillus niger and the causative agent of Fusarium wilt,
Fusarium oxysporum f.sp. lycopersici, commensurate with
the activity of commercially available fungicide ‘Benomyl’







































































Figure 7 Compounds produced by biotechnological use of CYP105s.
The structural feature introduced by the CYP105 is arrowed, and the
CYP105 involved is indicated.
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antifungal exhibits). The filipin biosynthetic pathway,
including the P450s, may be amenable to genetic engi-
neering to alter the structure and fungicidal specificity of
the products. This has been achieved in Streptomyces pre-
viously for polyene macrolide biosynthetic pathways
which include P450 enzymes. For example, nystatin
derivatives were generated by disruption of one of the
P450 enzymes involved in oxidative tailoring modifica-
tions during the final steps of nystatin (Fig. 3) biosynthe-
sis (Brautaset et al. 2011). The possibility, therefore, of
developing a range of fungicidal compounds based on fil-
ipin biosynthesis in streptomycetes is an attractive one.
Heterologous expression of the CYP105A1 from
S. griseolus in Bacillus megaterium MS941 allowed high
scale production of 3-hydroxylated derivatives of the sul-
fonylurea drugs glibenclamide and glimepiride (Kleser
et al. 2012) (Fig. 7). These are widely used in the treat-
ment of type 2 diabetes, which is increasingly common as
it is often a consequence of being overweight or obese
and new drugs for effective treatment are constantly
sought (Banerji and Dunn 2013). Both glibenclamide and
glimepiride are known to increase insulin secretion and
promote normoglycaemia, thereby mitigating the exten-
sive systemic damage that can be caused by the hyper-
glycaemia associated with diabetes. Hydroxylated
derivatives of the sulfonylurea drugs could be used as
platform compounds for development of the next genera-
tion of diabetic medicines. Interestingly, two expression
systems were tried, with and without a complementary
redox system also being expressed. No evidence was
reported of an increase in productivity with the addi-
tional redox system, suggesting B. megaterium is able to
provide the necessary electron transfer system (Kleser
et al. 2012). The extremely versatile CYP105A1 has also
been expressed in E. coli with redox partners from Schizo-
saccharomyces pombe and used to catalyse the hydroxyl-
ation of the resin compound abietic acid at C15 to give
15-hydroxyabietic acid (Janocha et al. 2013) (Fig. 7). This
compound can then be used to synthesize 15-hydroper-
oxyabietic acid (15-HPA), a major allergen. Production
of 15-HPA in pure form using bioconversion by
CYP105A1 promises to be useful in allergy testing (Jano-
cha and Bernhardt 2013).
Other potential biotechnological uses for CYP105s
include the conversion of diosgenin to isonuatigenone by
CYP105C from S. virginiae IBL14, described above
(Fig. 2) (Wang et al. 2007, 2009b). CYP105D7, involved
in pentalenic acid biosynthesis in S. avermitilis, has also
been shown to catalyse regiospecific hydroxylation of
isoflavones such as daidzein both in vitro and in vivo
(Pandey et al. 2010). The product of daidzein oxidation,
7,30,40-trihydroxyisoflavone (Fig. 7), is of interest due to
its enhanced antioxidant, anti-inflammatory and anti-
allergenic activities compared to daidzein itself (Park
et al. 2008). CYP105D8, CYP105B2, CYP105AA1 and
CYP105AA2 from strains of Streptomyces tubercidicus
were all found to catalyse oxidation of the 4″-hydroxy
group of avermectin to form 4″-oxoavermectin (Jung-
mann et al. 2005) (Fig. 7). Biotechnological production
of 4″-oxoavermectin would reduce the synthetic route
to from avermectin to emamectin (4″-deoxy-4″-meth-
ylaminoavermectin B), an agriculturally important insec-
ticide, from four steps (Cvetovich et al. 1994) to two, by
eliminating the need for protection of other alcohol
functionalities during oxidation to 4″-oxoavermectin.
Indeed, if S. avermitilis could be engineered to produce
4″-oxoavermectin directly, only a single step would then
be required for conversion to emamectin.
An excellent example of a CYP105 enzyme being uti-
lized in a biotechnological application is seen in PsmA, a
CYP105D homologue from Streptomyces bungoensis
A-1544, for the production of the macrolide pladienolide
D (Fig. 7). Pladienolides are 12 membered ring structures
produced as specialized metabolites by Streptomyces plat-
ensis Mer-11107, by the action of a PKS and several post-
PKS modifying enzymes (including a P450 belonging to
the CYP107 family) (Machida et al. 2008b). Pladienolides
are of interest because they show potent anti-tumour
activity, targeting the protein component of splicing factor
SF3b. Pladienolide D, which is a minor product, was
reported as the most promising therapeutic candidate,
and a derivative of this compound was found to be the
most potent and have the best physicochemical properties
for further pharmaceutical development (Machida et al.
2008a). Streptomyces bungoensis A-1544 was found to cata-
lyse the hydroxylation of pladienolide B, the major pladie-
nolide, to pladienolide D. Overexpression of psmA
resulted in a 15-fold increase in biotransformation of pla-
dienolide B to pladienolide D (Machida et al. 2008a). A
further development saw the heterologous expression of
PsmA in S. platensis, allowing high level pladienolide D
production in a one-step process (Machida et al. 2009). A
semi-synthetic analogue, E7107, has shown such potency
for inducing remission in lung cancer models, it has pro-
gressed to clinical trials (Podust and Sherman 2012).
Future perspectives
CYP105s form a fascinating family of enzymes. Histori-
cally investigated for their roles in xenobiotic degradation,
they are more recently revealed as essential components in
several diverse biosynthetic clusters and appreciated for
their versatility in biotechnological applications. Further
work will no doubt extend the industrial roles to which
these enzymes can be applied, and the clinical uses that
the bioactive natural products they help biosynthesize can
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be put to, utilizing the ability of CYP105s to accommo-
date a wide variety of substrates to generate structurally
diverse or novel compounds for further use. In ecological
terms, there remains much we do not know about
CYP105s. The high level of conservation of this family
across the genus argues for important functions within
the cell, but without investigation of the enzymes in vivo
with consideration of their natural environment, their
intrinsic value to the cell remains a mystery.
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